|
Video: What is a Stock Split?
|
|
Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease, cancer and selected other diseases. Co.'s main galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. GR-MD-02 has the potential to treat various diseases due to galectin-3's involvement in multiple main biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death). According to our Galectin Therapeutics stock split history records, Galectin Therapeutics has had 2 splits. | |
|
Galectin Therapeutics (GALT) has 2 splits in our Galectin Therapeutics stock split history database. The first split for GALT took place on September 20, 1999. This was a 2 for 1
split, meaning for each share of GALT owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. GALT's second split took place on March 23, 2012. This was a 1 for 6 reverse split, meaning for each 6 shares of GALT owned pre-split, the shareholder now owned 1 share. For example, a 2000 share position pre-split, became a 333.333333333333 share position following the split.
When a company such as Galectin Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. When a company such as Galectin Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Galectin Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 333.333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Galectin Therapeutics shares, starting with a $10,000 purchase of GALT, presented on a split-history-adjusted basis factoring in the complete Galectin Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$13.58 |
|
End price/share: |
$2.39 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-82.40% |
|
Average Annual Total Return: |
-15.95% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,760.29 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
09/20/1999 | 2 for 1
| 03/23/2012 | 1 for 6 |
|
|